Amgen enters its May 19 earnings call with options traders at their most defensive in months, a broad insider-selling cluster just behind it, and a stock that has lost 7% over the past month.
The sharpest signal heading into the print is in options. Demand for downside protection has jumped well above recent norms — the put/call ratio climbed to 0.95 on May 15, almost three standard deviations above its 20-day average of 0.86. That z-score of 2.93 is among the most elevated readings of the past year; the 52-week high on the PCR is 1.11, so the ratio isn't at a record, but the velocity of the move is notable. The stock closed at $326.31 on Friday, down 2.95% on the day and off 1.6% across the week, putting it well inside the $352 consensus price target territory — but that gap has been closing steadily as the stock drifts lower.
Short interest tells a less alarming story. At 2.2% of the free float as of May 14, positioning is modest by any standard. What's interesting is the trajectory: SI peaked near 2.52% of float in early May — a level not seen since late April — and has been unwinding for the past week, falling roughly 10% in that time. That retreat coincided with the stock's slide, suggesting some shorts chose to cover into weakness rather than press the trade. Borrow conditions reinforce the lack of urgency on the bear side. Cost to borrow is just 0.40%, having eased about 11% over the past week despite rising nearly 51% over the prior month. Availability remains extremely loose, with the lending pool well below any squeeze threshold — utilization peaked at just 4.4% across the past year and is now down to 1.5%.
Analyst opinion has been drifting cautiously ahead of the print. Piper Sandler trimmed its price target to $427 on May 14 while holding an Overweight rating — the stock still trades at a wide discount to that figure, which is worth noting. Guggenheim nudged its neutral target down to $340, closer to where the stock actually trades. On the bullish side, UBS lifted to $400 in April and still carries a Buy. Morgan Stanley's Equal-Weight with a $326 target — essentially at the current price — captures the fence-sitting mood accurately. The consensus stays at Buy with a mean target around $352, but the direction of recent moves has been target trims rather than raises. Bears point to pipeline execution risk on MariTide and olpasiran, potential revenue erosion from ageing blockbusters like Prolia and Otezla, and total revenue guidance bracketed between $36B and $38B. Bulls counter with the depth of the drug portfolio and the growth runway in recently launched products. The stock's PE sits near 14.75x, having contracted about 0.6 turns over the past month, and the EV/EBITDA has inched down fractionally, suggesting valuation has become slightly less demanding even as sentiment has softened.
The insider picture adds a layer of colour without being dramatic. Nine executives sold shares on May 7 at $331.11 per share — including CEO Robert Bradway, CFO Peter Griffith, and CTO David Reese — collectively offloading around $1.7 million in total proceeds. Every trade on the day carried a significance score of 1 out of 10, pointing to routine pre-planned disposals rather than discretionary bearish conviction. Net insider activity over 90 days is marginally positive at around 14,000 shares bought — so the cluster of sells is clearly scheduled rather than opportunistic. The institutional ownership base is steady: Vanguard, BlackRock, and Capital Research collectively hold over 27% of shares, and recent filings show most large holders adding, not cutting.
The last earnings print on April 30 produced a 1-day decline of 2.4% and a 5-day move of -2.6%, a pattern consistent with a stock where results are in line but guidance or pipeline commentary disappoints at the margin. With options pricing in heightened caution and the stock already bruised going into May 19, the reaction to the upcoming call is less about whether the quarter was clean and more about what management says on MariTide data timelines and the pace of new product uptake. Close peers were broadly lower on the week too — INCY fell 3.3% and REGN dropped 2.3% — framing AMGN's decline as partly sector-wide rather than purely stock-specific.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
